Group 1: Company Overview - Chengdu Zeling Biopharmaceutical Technology Co., Ltd. (Zeling Bio) has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, with Jefferies and CICC as joint sponsors [1] - The company recently completed a C round financing of nearly 600 million RMB, led by Daming Capital and Qiming Venture Partners, bringing its valuation to approximately 3.411 billion RMB [1] - Zeling Bio was founded in 2019 and focuses on innovative therapies for blood diseases, tumors, central nervous system disorders, and immune/inflammatory diseases [2] Group 2: Product Pipeline - Zeling Bio has established three technology platforms: ZeniFol for small molecule drug identification and optimization, ZeniMin for AI-driven drug development, and ZeniScreen for clinical-related screening and target discovery [2] - The company has a pipeline of eight products, including two core products in Phase III clinical trials, two candidates in clinical stages, and four in preclinical stages [3] Group 3: Key Products - The lead product, Malate Fluorotinib (FM), is a first-in-class triple-target inhibitor aimed at treating myeloproliferative neoplasms, including myelofibrosis and polycythemia vera [4] - FM is positioned against Novartis' Ruxolitinib, which has been a cornerstone therapy since its approval in the U.S. in 2011 [4] - Zeling Bio plans to submit a new drug application for FM to the National Medical Products Administration (NMPA) in 2027 and has initiated a Phase IIb head-to-head clinical trial against Ruxolitinib [6] Group 4: Financial Performance - Zeling Bio reported revenues of 19.66 million RMB and 7.12 million RMB for 2024 and the first three quarters of 2025, respectively, with significant losses of 91.66 million RMB and 119.04 million RMB during the same periods [9] - The primary reasons for the losses are high R&D expenditures and changes in the value of redeemable debt, with a significant focus on the two core products FM and PM [10] Group 5: Funding and Shareholding - The company has completed five rounds of financing, raising a total of 1.18 billion RMB, with investors including Qiming Venture Partners and Tencent [12] - Chen Lijuan holds a combined direct and indirect stake of 25.6%, making her the largest shareholder group [14]

Group 1 - The core viewpoint of the article is that Zeling Bio has submitted its listing application to the Hong Kong Stock Exchange, with Jefferies and CICC as joint sponsors [1] - Zeling Bio is a late-stage clinical biotechnology company focused on developing differentiated small molecule therapies to address significant medical needs in hematological diseases and oncology [1] - The company has established a diversified pipeline consisting of eight proprietary assets, which includes two core products, two clinical-stage candidates, and four preclinical-stage candidates as of January 5, 2026 [1] Group 2 - Among the candidates, two have entered Phase 3 registrational clinical trials: Malonic Acid Fluorotidine (FM) for treating myelofibrosis and Puyisitan Sulfate (PM) for treating relapsed/refractory diffuse large B-cell lymphoma [1] - Currently, Zeling Bio has no products approved for commercial sale, with other income and revenue reported as 19.661 million and 7.126 million respectively for the periods ending December 31, 2024, and September 30, 2025 [1]